Issue

Vol. 66 No. 6: Issue 6

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Interleukin-6 role in the severity of COVID-19 and intensive care unit stay length

https://doi.org/10.14715/cmb/2020.66.6.3
Ruqaya Muhammed Ghareeb Taher Al barzin
Microbiology Unit, Department of Basic Science, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region-Iraq
Shler Ghafour Raheem
Microbiology Unit, Department of Basic Science, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region-Iraq.
Pinar Khalid Khudhur
Microbiology Unit, Department of Basic Science, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region-Iraq
Rahim Abdulkarimi
Department of Environment, Boukan Office, West Azerbaijan Province, Iran
Esmaeil Mohammadnejad
Nursing Education, Department of Medical-Surgical Nursing and Basic Sciences, School of Nursing & Midwifery, Tehran University of Medical Sciences, Tehran, Iran
Amir Tabatabaee
Nursing Department, Quchan Branch, Islamic Azad University, Quchan, Iran

Corresponding Author(s) : Ruqaya Muhammed Ghareeb Taher Al barzin

ruqaya.taher@hmu.edu.krd

Cellular and Molecular Biology, Vol. 66 No. 6: Issue 6

Abstract

Evaluation of cytokine production in COVIID-19 disease, in which the cytokine storm is one of the most important pathological features in complicated cases, especially interleukin 6 as a pre-inflammatory cytokine that exacerbates the immune response, could help determine the pathophysiology of the disease. Examining the level of this cytokine along with other related factors can help to better understand the pathogenesis of this disease. In this cross-sectional study, 48 patients with COVID-19 whose disease was confirmed by swap testing were evaluated. The demographic information of the individuals, the symptoms of the disease, and the ward in which they were admitted were recorded. Blood samples were taken from patients to test for interleukin-6 levels by electrochemiluminescence immunoassay (ECLIA, Roche Diagnostics). Due to the lack of specific treatment protocols for patients and the use of supportive treatments based on meeting the nutritional needs for all patients, blood albumin levels and nutritional status of patients were also evaluated using Subjective Global Assessment (SGA) Form. Their calorie intake was assessed by calculating the number of calories received based on the type of nutrition and compared to the required amount calculated through the Harris-Benedict equation. 48 laboratory-confirmed 2019-nCoV infected patients were included in the study with the mean age of 46.4 ± 8.3 years. 21 patients were admitted to the intensive care unit (ICU). There was no significant difference between the ICU admitted and patients admitted inward in terms of demographic characteristics, and history of previous diseases (p > 0.05). The average interleukin 6 (IL-6) in patients was 72.3±34.4 pg/ml. ICU admitted patients had higher IL6 levels (p=0.001). The mean interleukin 6 level was 89.04±34.1 pg/ml in patients admitted for less than 7 days and it was significantly higher (119.2±28.3) in patients hospitalized for more than 7 days (p=0.001). there was no significant difference in terms of nutritional status and albumin level between ICU admitted and ward admitted patients (p >0.05). Our study shows that there may be possible associations of IL6 and disease severity and ICU stay length.

Keywords

COVID-19 IL-6 2019-nCoV Intensive care unit.
Taher Al barzin, R. M. G., Ghafour Raheem, S., Khudhur, P. K., Abdulkarimi, R., Mohammadnejad, E., & Tabatabaee, A. (2020). Interleukin-6 role in the severity of COVID-19 and intensive care unit stay length. Cellular and Molecular Biology, 66(6), 15–18. https://doi.org/10.14715/cmb/2020.66.6.3
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents 2020 Feb 17:105924.
  2. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033-4.
  3. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect 2020 Mar 11.
  4. Tanaka T, Narazaki M, Masuda K, Kishimoto T. Regulation of IL-6 in immunity and diseases. In regulation of cytokine gene expression in immunity and diseases. Adv Exp Med Biol 2016; 941:79-88. doi: 10.1007/978-94-024-0921-5_4.
  5. Yu H, Zou W, Wang X, Dai G, Zhang T, Zhang G, Xie K, Wang J, Shi H. Research Note: Correlation analysis of interleukin-6, interleukin-8, and CC motif chemokine ligand 2 gene expression in chicken spleen and cecal tissues after Eimeria tenella infection in vivo. Poultry Sci 2020; 99(3):1326-31.
  6. Garbers C, Rose-John S. Dissecting interleukin-6 classic-and trans-signaling in inflammation and cancer. In Inflammation and Cancer 2018 (pp. 127-140). Humana Press, New York, NY.
  7. Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca MV. The role of interleukin 6 during viral infections. Frontiers Microbiol 2019; 10:1057.
  8. Romano L, Bilotta F, Dauri M, Macheda S, Pujia A, De Santis GL, Tarsitano MG, Merra G, Di Renzo L, Esposito E, De Lorenzo A. Short Report–Medical nutrition therapy for critically ill patients with COVID-19. Eur Rev Med Pharmacol Sci 2020; 24:4035-9.
  9. Detsky AS, Baker JP, Johnston N, Whittaker S, Mendelson RA, Jeejeebhoy KN. What is subjective global assessment of nutritional status? J Parenter Enteral Nutr; 11(1):8-13.
  10. Rostamian A, Ghazanfari T, Arabkheradmand J, Edalatifard M, Ghaffarpour S, Salehi MR, Raeeskarami R, Mahmoodi Aliabadi M, Rajabnia Chenary M, Mirsharif E, Jamali D, Sattarian MR, Hosseinieselki Sari S, Jafarpour S, Najafizadeh R, Naghizadeh MM. Iran COVID-19 Immunological Study: Remarkable Level of Interleukin-6 in Iranian COVID-19 Hospitalized Patients (4/4/2020). Available at SSRN: https://ssrn.com/abstract=3571554.
  11. Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: A Systematic Review and Meta-Analysis. medRxiv. 2020 Jan 1.
  12. Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. J Parenter Enter Nutr 2019; 43(2):181-93.
  13. Dutton J, Campbell H, Tanner J, Richards N. Pre"dialysis serum albumin is a poor indicator of nutritional status in stable chronic haemodialysis patients. EDTNA"ERCA J 1999; 25(1):36-7.
  14. Milan Manani S, Virzí¬ GM, Clementi A, Brocca A, de Cal M, Tantillo I, Ferrando L, Crepaldi C, Ronco C. Pro-inflammatory cytokines: a possible relationship with dialytic adequacy and serum albumin in peritoneal dialysis patients. Clin Kidney J 2016 Feb 1;9(1):153-7.
  15. Bordbar M, Darvishzadeh R, Pazhouhandeh M, Kahrizi D. An overview of genome editing methods based on endonucleases. Modern Genetics J 2020; 15(2): 75-92.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 1020 Download : 578

Most read articles by the same author(s)